This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers

This study has been completed.
Information provided by:
Dong-A ST Co., Ltd. Identifier:
First received: July 14, 2010
Last updated: September 29, 2014
Last verified: September 2014
This is a double-blind, randomized, placebo-controlled, 4-period, cross-over clinical trial. The study is designed to evaluate the safety and local tolerability of DA-6034 upon single and repeated-dose topical application to the both eyes in healthy volunteers.

Condition Intervention Phase
Dry Eye Syndrome Drug: DA-6034 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Local Tolerability After Administration of Eye Drop DA-6034 in Healthy Volunteers(Phase I)

Further study details as provided by Dong-A ST Co., Ltd.:

Primary Outcome Measures:
  • Ocular symptomatology, ophthalmologic tests [ Time Frame: Single dose: up to 5 days, Multiple dose: up to 15 days ]

Secondary Outcome Measures:
  • Adverse events, vital signs, physical examinations, ECG findings, clinical laboratory tests, ocular symptomatology, ophthalmologic tests, Unanesthetized Schirmer tests [ Time Frame: Single dose: up to 10 days, Multiple dose: up to 20 days ]

Study Start Date: September 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DA-6034 Drug: DA-6034
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 20-50 year-old healthy subjects

Exclusion Criteria:

  • Presence or history of dry eye or other ocular or systemic diseases
  • Corrected visual acuity less than 20/40 in either eye at the screening
  • Any eye surgery or laser eye surgery within the past six months
  • Intraocular pressure greater than 22 mmHg in either eye at the screening
  • Break-up time less than 10 sec with OSDI score corresponding to mild to severe dry eye symptoms in either eye at the screening
  • Unanesthetized Schirmer scores <10 mm in either eye at the screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01162954

Korea, Republic of
Clinical Research Institue, Seoul National University Hospital
Seoul, Chongno-Gu, Yon-Gon Dong 28, Korea, Republic of, 110-744
Sponsors and Collaborators
Dong-A ST Co., Ltd.
Principal Investigator: Kyung-Sang Yu, M.D., Ph.D., M.B.A Clinical Research Institute, Seoul National University Hospital
  More Information

Responsible Party: Jeong-Seong Hong/Assistant Manager, Clinical Development Team 1 Identifier: NCT01162954     History of Changes
Other Study ID Numbers: DA6034_DES_I
Study First Received: July 14, 2010
Last Updated: September 29, 2014

Keywords provided by Dong-A ST Co., Ltd.:
Eye drop, Dry eye

Additional relevant MeSH terms:
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Lacrimal Apparatus Diseases
Eye Diseases
Conjunctival Diseases
Corneal Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nasal Decongestants
Vasoconstrictor Agents
Respiratory System Agents processed this record on July 21, 2017